We fight for human health.

CureVac is the first company to successfully harness messenger RNA (mRNA) for medical purposes. The principle is promising: use natural mRNA as a data carrier to instruct the human body to produce its own proteins to fight a wide range of diseases.

  • Lilly and CureVac Announce Global Collaboration to Develop mRNA Cancer Vaccines

    Press Release of October 18, 2017

    Read more
  • "A successful founder off the beaten path"

    CureVac's history published in Nature Biotechnology on Oct 11, 2017

    Read more
  • Publication in EMBO Molecular Medicine Demonstrates CureVac’s Proprietary mRNA Technology Enables Antibody Mediated Therapies Against Infectious Agents, Toxins and Tumors

    Press Release of August 15, 2017

    Read more
  • CureVac Announces Publication in The Lancet of First-Ever Human Proof-of-Concept Study Investigating the Safety and Immunogenicity of a Prophylactic mRNA Vaccine

    Press Release of July 26, 2017

    Read more
  • Register now for the 5th International mRNA Health Conference

    November 1-2, 2017, Berlin, Germany

    Read more
  • Work@CureVac

    Do you want to fight together with us for human health? You will find current vacancies on our CareerPortal.

    Read more